Mettler-Toledo InternationalMTD
Recorded

Mettler-Toledo International UBS Global Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 0Duration35 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Doug SchenkelAnalyst

Good morning, everybody. I am Doug Schenkel, and on behalf of UBS, it is my pleasure to welcome Shawn Vadala, Chief Financial Officer of Mettler-Toledo. Thanks for being with us this morning.

Shawn VadalaCFO

Yeah. Hey, it is great to be here. Thanks for hosting me, Doug.

Doug SchenkelAnalyst

I think Mettler is well-known to everybody here, everybody on the line, but it has evolved from its roots in precision weighing into a global leader across laboratory, process analysis, industrial, and product inspection markets with what it believes are number one positions in most, if not all of those areas. The company did a really impressive investor day earlier this week. The company is now leveraging that leadership position and a long track record of strong best-in-class execution to capture growth from automation, digitalization, and potential reshoring opportunities. A lot of exciting things to talk about. That really probably sets the stage for what we are going to go through as a roadmap. I want to talk about the analyst day. Maybe, yeah, we have a few questions there, and I want to talk about the messaging there.

Doug SchenkelAnalyst

Kind of sort of related, maybe we could just start with a state of the union, state of the company, keeping in mind you grew 6% or so organic in the third quarter. At the analyst day and on that call, you laid out an initial 2027 outlook of around 5% local currency revenue growth, low double-digit earnings growth. What drove the strength in the quarter?

Doug SchenkelAnalyst

As you are thinking about 2027, what are you assuming in terms of the demand environment across your key end markets?

Shawn VadalaCFO

Okay, great. Well, thanks, Doug. There is a lot to unpack there.

Shawn VadalaCFO

Yeah. I look forward to the next half hour.

Shawn VadalaCFO

Yeah, go. Oh, yeah. So, hey, I'll start with the third quarter.

Shawn VadalaCFO

Very pleased with the third quarter, 6% growth, as you mentioned. What was nice to see is the breadth of the growth in our product portfolio. On the industrial side, we were kind of comping, I think, a double-digit growth on the core industrial side in the year before. So, it was really nice to see growth on top of that. The trends that we continue to talk about with customer automation and digitalization really continued to We experienced that. On the laboratory side, what was nice is that if you think about the beginning of the year, bioprocessing had really good trends, and then in the second quarter, we started to see analytical instruments, laboratory balances, like that, products that tend to sell to the QA/QC bench doing very well.

Shawn VadalaCFO

By Q3, we were starting to see stuff on the early research side. For the first time in quite a while where we had very good growth in liquid handling, the pipettes and the pipette tips. So, that was also really encouraging to see. Geographically, Asia Pacific was clearly the highlight. Patrick and I were just there in September at the conclusion of our annual budget tour. High energy, as you can imagine. Each year when we go there, I feel like we're kind of getting a pulse on the situation, and we walked away really encouraged. We were literally accelerating some additional investments into the region in terms of growth investments while we were there, just because not only China, but the other parts of Asia Pacific. Organically, Asia Pacific grew 13% in the quarter, but China also grew 13% in the quarter.

Shawn VadalaCFO

That was great to see. We talked a little bit about that region and emerging markets more broadly in our second quarter call, and it was nice to see how that was playing out. As we start talking LRPs and things like that, emerging markets in general, I think, is an area where we're really encouraged. Then, you kind of take that, and we were able to get 13% EPS growth, which we felt very good about. That includes us continuing to invest in the business for the future, which we can talk a little bit more about with the LRP. As we kind of start to segue into 2027 and stuff like that, we do feel like market conditions now are better than what we were seeing. We're always a little bit cautious in how we look at things.

Shawn VadalaCFO

We're a little bit more cautious on Europe, as an example. I think the European continent has experienced higher energy costs relative to the rest of the world. I think that's going to influence some of their decision-making. In some of our core segments there, probably are investing more outside of Europe than they are in Europe at the moment. But still, we feel like market conditions generally are pretty good kind of going into next year. Now, maybe companies start a little cautious at the beginning of the year, but I think generally, we have probably more optimism at this point than we did a year ago.

Doug SchenkelAnalyst

Okay. That is great. A couple follow-ups. You mentioned Asia. You talked about China.

Doug SchenkelAnalyst

China is about 16% of revenue. You had a really good third quarter. You are tracking to about 10% growth for the year.

Doug SchenkelAnalyst

That is right. You expect it to grow, I think you guys described that growing around the company average, plus or minus, over the long term.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day